The global single-use bioreactor (SUB) market was valued at USD 11.63 billion in 2024 and is forecasted to reach USD 39.67 billion by 2035. This represents a robust Compound Annual Growth Rate (CAGR) of 11.80% during the forecast period from 2025 to 2035.
Global Single-use Bioreactors Market Size, Trend & Opportunity Analysis Report, by Product Type (Single-use, Reusable), Cell (Mammalian, Bacterial, Yeast), and Forecast, 2025-2035
Report Code: LSDB51Author Name: Isha PaliwalPublication Date: August 2025Pages: 293
Available In:
Global Single-use Bioreactors Market Size, Opportunity Analysis and Forecast, 2025-2035
Publication Date: Aug 16, 2025Pages: 293
Market Definition and Introduction
The Worldwide Single-Use Bioreactor market was valued at USD 11.63 billion in 2024, and it is forecasted to reach USD 39.67 billion by 2035, thereby growing at a CAGR of 11.80% during the forecast period 2025-2035. In the face of increasing global requirements for vaccines, monoclonal antibodies, and cell and gene therapeutics, biopharmaceutical manufacturers have escalated their scale-up productions to meet these demands, whereby the single-use bioreactor (SUB) adoption represents a rapid and paradigm-changing shift for bioprocessing.
These disposable systems save users from time-consuming activities associated with cleaning and sterilizing, thus giving speed, flexibility, and cost-effectiveness to upstream processes.
Transitioning from traditional stainless-steel bioreactors to single-use formats is not just an evolution of functionality but is a strategic repositioning. This enables facilities to work in a multiproduct environment with reduced cross-contamination risk and faster changeover, shortening time to market further. The modular and scalable nature of SUBs adds batch-size flexibility, thus becoming a necessity for small-volume, high-value biologics, particularly in cell therapy and personalized medicine manufacturing. Increasing pressure to deliver safe and effective biologics faster is generating unprecedented momentum for single-use platforms.
In addition, SUBs are becoming central to the design of next-generation biopharma facilities with the rise of decentralized biomanufacturing and increased demand for mobile, GMP-compliant production suites. Firms are introducing advanced automation, AI-enabled process analytics, and digital twins into SUB platforms to enhance yields and guarantee reproducibility. As regulators start to relax restrictions for single-use systems and innovation in sustainable bioplastics gathers steam, the market finds itself in the midst of accelerated innovation and worldwide expansion, driven both by necessity and opportunity.
Recent Developments in the Industry
- In April 2024, Sartorius AG announced the launch of the BIOSTAT STR- Generation 4 system, a new kind of single-use bioreactor platform dedicated to viral vector and cell therapy production with all the modern bells and whistles with respect to process control, automation, and closed-system integration.
- In July 2024, Thermo Fisher Scientific announced an investment of USD 125 million to expand its biologics manufacturing facility in Singapore, focusing on the integration of single-use bioreactor systems for GMP-scale vaccine and therapeutic production.
- In January 2024, Cytiva Danaher company released its FlexFactory- Xpress solution featuring ready-to-deploy single-use bioreactors designed for fast implementation in mobile bioprocessing suites, thus drastically shortening setup timelines.
Market Dynamics
This simply means acceleration in producing larger volumes of biologics.
By transforming the products into high-value biologics and therapeutic products such as monoclonal antibodies, cell therapies, and recombinant proteins, the biopharmaceutical industry is tending towards the area of producing high-value biologics. Because of the nature of their processing, single-use bioreactors are increasingly attracting manufacturers to rationalize production cycles and manage costs. Modularity and scalability allow those implementing such a solution to make their response to changing requirements at a particular stage, especially during development phases such as clinical trials.
Increasing Demand for Flexibility and Contamination-Free Production Environment in Biomanufacturing
Traditional bioreactors are configurable enough to require rigorous cleaning validation and expose cross-product contamination risks. Single-use systems address this dilemma head-on: every run is a clean slate. It is especially critical for multiproduct plants and CMO/CDMOs, which essentially provide diverse therapeutic pipelines and thereby allow switching products rapidly with no concerns about sterility.
Emerging Most Ultimate Features of Automated Digitized Integrated Single-Use Bioreactor Platforms Across Facilities
SUB platforms are changing the process reliability and integrity of data through their automation and digital control systems. The result: very reliable and constantly processed smart bioreactors, which address state-of-the-art process analytics and real-time monitoring, resulting in strong consistency and adaptive optimization of processes, which are essential in maintaining stringent compliance with GMP and higher productivity gains within the overall bioprocess.
Emerging Personalized Medicine and Batch Conditioning Change Paradigms in Bioreactor Needs
Personalized medicines and orphan drugs have set in motion a paradigm shift toward small-batch manufacturing systems. The high flexibility of single-use bioreactors, with super-low hold-up volumes and adjustable geometries-makes them ideal for flexible manufacturing models that produce less waste and lower cost per batch, defining requirements in these niche markets.
Sustainability Concerns Heighten Innovations in Biodegradable and Recyclable Disposable Bioreactor Bags
The fairly adamant concern about the environmental impact of single-use systems is surely changing pages toward a whole new sustainability story, with ongoing studies on recyclable polymers and development towards biodegradable bags. What is even more encouraging is the trend being set by many of their top manufacturers toward closed-loop recycling of these product offerings, a seeming tilt to lifecycle sustainability balance with reduced energy use owing to the smaller cleaning Professor Boxes.
Attractive Opportunities in the Market
- Expanding Biologics Market - Pipeline growth in mAbs and fusion proteins fuels scalable SUB demand.
- Cell and Gene Therapy Surge - SUBs offer high containment and scalability for sensitive cell lines.
- Decentralized Biomanufacturing - SUBs support mobile, modular GMP facilities globally.
- Digital Bioprocessing - Integration of PAT tools and AI enhances process predictability and control.
- Reusable-Single Use Hybrids - Innovations bridge reusability and disposability for performance-flexibility balance.
- Asia-Pacific Investment - Regional biomanufacturing initiatives drive localized SUB adoption.
- Reduced Validation Time - Disposable systems eliminate CIP/SIP, fast-tracking facility readiness.
- Low Capital Footprint - SUBs minimize infrastructure costs in greenfield biomanufacturing projects.
Report Segmentation
By Product Type: Single-use, Reusable
By Cell: Mammalian, Bacterial, Yeast
By Region: North America (U.S., Canada, Mexico), Europe (UK, Germany, France, Spain, Italy, Spain, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea, Rest of Asia-Pacific), LAMEA (Brazil, Argentina, UAE, Saudi Arabia (KSA), Africa Rest of Latin America)
Key Market Players: Sartorius AG, Thermo Fisher Scientific Inc., Danaher Corporation, Eppendorf AG, Merck KGaA, PBS Biotech, Inc., Cellexus Ltd, ABEC Inc., Celltainer Biotech B.V., Applikon Biotechnology (a Getinge company)
Report Aspects
Base Year: 2024
Historic Years: 2022, 2023, 2024
Forecast Period: 2025-2035
Report Pages: 293
Dominating Segments
Operational Simplicity and Cost-Effective Flexibility in Bioreactors
Single-use bioreactor systems have arguably swept the market clean owing to their capability of drastically shortening turnaround times, lessening contamination risks, and cutting infrastructure requirements. In addition, thanks to their modular design, these systems can be scaled up straightforwardly, making them rather popular in clinical and commercial production lines. With the rest of the world regaining the thrust of disposable technologies by different regulatory agencies, it is forecasted that this adoption will continue its phenomenal growth trajectory with both giant biopharma and new biotech companies.
Applications of Mammalian Cell Lines are Leading Market Demand Because of Their Wide Application in the Production of Biologics
CHO and HEK cell lines are the most common expression systems used in the biopharmaceutical production arena to date. Mammalian cells usually require very strict controlled environments that single-use systems would be able to incorporate very well, particularly using improvements in oxygenation, tighter pH control, and customizable bioprocess parameters. The share of this segment soars high since it's at the center of the production of therapeutic proteins, vaccines, and gene therapies with high fidelity and yield.
Finds a Niche in Long-haul, High-throughput Bioproduction Operation
Reusable bioreactor segment, while not very big, is relevant for some applications at a large scale and high volume where long batch durations justify upfront investment and validation costs. This segment experiences a much slower growth rate owing to agility within manufacturing and flexibility in facility design, with single-use systems offering the advantages thereof.
Key Takeaways in the Market
- Single-use Bioreactor Leadership - Disposable systems dominate due to scalability, sterility, and speed.
- Mammalian Cell Dominance - CHO and HEK-based processes drive biopharma reliance on SUBs.
- Reusable Systems See Limited Growth - Reusables persist in niche, large-batch production.
- Automated Process Control - Real-time analytics and AI transform SUB consistency and outcomes.
- Sustainability Innovation - Recyclable bags and lower water/energy use improve ecological balance.
- Regulatory Acceptance - Agencies embracing SUB standards accelerate global adoption.
- CDMO Preference - Contract manufacturers use SUBs to handle diverse client pipelines.
- Global Infrastructure Growth - APAC and LATAM bioproduction centers stimulate equipment demand.
- Personalized Medicine Compatibility - Small-batch therapies benefit from SUB-s low-volume capacity.
- Hybrid Systems Emerge - Flexible reactor designs combine disposability with durability.
Regional Insights
North America is the Market Leader through Innovation, Advanced Infrastructure, and Regulatory Maturity
Currently, North America continues to take a good portion of the world's single-use bioreactors market. The primary reason for this is the country's strong biopharmaceutical innovation ecosystem, advanced biomanufacturing infrastructure, and the rapid uptake of modern production technologies. The U.S. is the global hub and center of gravity for biologics development and thus offers great potential benefits for the integration of SUBs in clinical and commercial pipelines. The region's dominant position is further fortified by strategic collaborations between CDMOs and large biopharma companies.
Europe follows with the investment in biomanufacturing and regulatory harmonization efforts.
Like the rest of Europe, those countries such as Germany, Switzerland, and the U.K. continue to have a notable proportion of market share as they are also developing their capacity for producing biologics. Indeed, the region has implemented a very supportive regulatory framework, all of which are in line with GMP standards for single-use systems. Investment in pandemic preparedness and domestic vaccine production infrastructures has also catalyzed the use of SUBs across both public and private sector labs.
Asia-Pacific To Enjoy The Rapidest Growth Of Markets In the Future Due To Scaling Bioproduction In The Region
Asia-Pacific is going to grow at a very fast pace, strengthened by newly added local biologics pipelines, governmental support for establishing pharma manufacturing parks, and even a growing population excellently trained in biotechnology. Countries like China, South Korea, and India strategically focus on modular, cost-effective suites of bioproduction that prefer single-use technologies, and therefore, these make the region an ideal global site for next-gen manufacturing innovation.
Latin America and MEA Started to Integrate SUBs Slowly, Along with the Biomanufacturing Infrastructure Development
Still emerging, in terms of single-use bioreactor adoption, Latin America and the Middle East & Africa are starting to see increasing numbers of local adopters as they strengthen their production capabilities and forge partnerships with various global CDMOs. These initiatives are expected to improve standards of healthcare self-sufficiency and bring in more biopharmaceutical investments, attracted by regulatory reforms and capacity building.
Key Benefits for Stakeholders
- The report offers a quantitative assessment of market segments, emerging trends, projections, and market dynamics for the period 2024 to 2035.
- The report presents comprehensive market research, including insights into key growth drivers, challenges, and potential opportunities.
- Porter's Five Forces analysis evaluates the influence of buyers and suppliers, helping stakeholders make strategic, profit-driven decisions and strengthen their supplier-buyer relationships.
- A detailed examination of market segmentation helps identify existing and emerging opportunities.
- Key countries within each region are analysed based on their revenue contributions to the overall market.
- The positioning of market players enables effective benchmarking and provides clarity on their current standing within the industry.
- The report covers regional and global market trends, major players, key segments, application areas, and strategies for market expansion.
Frequently Asked Questions
Single-use bioreactors offer significant advantages in speed, flexibility, and cost-effectiveness. They eliminate time-consuming cleaning and sterilization (CIP/SIP) processes, reduce the risk of cross-contamination, and allow for faster facility changeovers. This modularity is particularly beneficial for multiproduct environments and shortening the time to market for new biologics.
Mammalian cell lines, specifically CHO (Chinese Hamster Ovary) and HEK (Human Embryonic Kidney) cells, lead the market demand. These cells are essential for producing high-fidelity therapeutic proteins, vaccines, and gene therapies, requiring the strictly controlled environments that modern SUBs provide through advanced oxygenation and pH control.
The industry is integrating advanced automation, AI-enabled process analytics, and digital twins into SUB platforms. These technologies enhance process reliability, guarantee reproducibility, and allow for real-time monitoring and adaptive optimization, which are critical for maintaining stringent GMP compliance and increasing yields.
North America is the current market leader due to its advanced biomanufacturing infrastructure and strong biologics innovation ecosystem. However, the Asia-Pacific region is projected to experience the fastest growth, driven by localized bioproduction initiatives, government support for pharma parks, and expanding biotech pipelines in countries like China, India, and South Korea.
SUBs are ideal for personalized medicine and orphan drug manufacturing because they support small-batch, high-value production models. Their high flexibility, low hold-up volumes, and adjustable geometries allow for cost-effective manufacturing with reduced waste, catering specifically to niche therapeutic markets.
To mitigate environmental impact, manufacturers are researching recyclable polymers and developing biodegradable bioreactor bags. There is a growing trend toward closed-loop recycling programs and the adoption of hybrid systems to balance the benefits of disposability with lifecycle sustainability.
Contract Development and Manufacturing Organizations (CDMOs) prefer single-use systems because they allow for the rapid switching between diverse client pipelines without concerns about sterility. The ""clean slate"" provided by every new disposable run is essential for managing multiple products within the same facility.
Key recent developments in 2024 include Sartorius AG’s launch of the BIOSTAT STR- Generation 4 for cell therapy, Thermo Fisher Scientific’s USD 125 million expansion of its SUB-integrated facility in Singapore, and Cytiva’s release of the FlexFactory-Xpress for rapid implementation in mobile bioprocessing suites.
Despite rapid growth, challenges include concerns over the environmental footprint of plastic waste, limitations in scalability for ultra-large batch volumes, regulatory variability across different regions, and the requirement for specialized training to manage increasingly complex, digitally integrated systems.
